MedMira Management

Management criteria checks 4/4

MedMira's CEO is Hermes Chan, appointed in Jul 2006, has a tenure of 17.75 years. directly owns 0.4% of the company’s shares, worth €144.28K. The average tenure of the management team and the board of directors is 10.2 years and 4.9 years respectively.

Key information

Hermes Chan

Chief executive officer

CA$100.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	17.8yrs
CEO ownership	0.4%
Management average tenure	10.2yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hermes Chan's remuneration changed compared to MedMira's earnings?
Date	Total Compensation	Salary	Company Earnings
Jan 31 2024	n/a	n/a	-CA$3m
Oct 31 2023	n/a	n/a	-CA$3m
Jul 31 2023	CA$100k	n/a	-CA$3m
Apr 30 2023	n/a	n/a	-CA$2m
Jan 31 2023	n/a	n/a	-CA$2m
Oct 31 2022	n/a	n/a	-CA$2m
Jul 31 2022	CA$100k	CA$100k	-CA$2m
Apr 30 2022	n/a	n/a	-CA$2m
Jan 31 2022	n/a	n/a	-CA$2m
Oct 31 2021	n/a	n/a	-CA$2m
Jul 31 2021	CA$100k	CA$100k	-CA$676k
Apr 30 2021	n/a	n/a	-CA$309k
Jan 31 2021	n/a	n/a	-CA$663k
Oct 31 2020	n/a	n/a	-CA$862k
Jul 31 2020	CA$151k	CA$151k	-CA$2m
Apr 30 2020	n/a	n/a	-CA$2m
Jan 31 2020	n/a	n/a	-CA$2m
Oct 31 2019	n/a	n/a	-CA$2m
Jul 31 2019	CA$191k	CA$191k	-CA$2m
Apr 30 2019	n/a	n/a	-CA$2m
Jan 31 2019	n/a	n/a	-CA$2m
Oct 31 2018	n/a	n/a	-CA$2m
Jul 31 2018	CA$193k	CA$188k	-CA$3m
Apr 30 2018	n/a	n/a	-CA$3m
Jan 31 2018	n/a	n/a	-CA$3m
Oct 31 2017	n/a	n/a	-CA$2m
Jul 31 2017	CA$191k	CA$188k	-CA$3m

Compensation vs Market: Hermes's total compensation ($USD73.17K) is below average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Hermes's compensation has been consistent with company performance over the past year.

CEO

Hermes Chan

17.8yrs

Tenure

CA$100,000

Compensation

Mr. Hermes Chan Co-Founded MedMira Inc. and has been its President since 2000 and Chief Executive Officer since July 24, 2006. Mr. Chan has been the Chief Executive Officer and President of MedMira Laborat...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hermes Chan	Co-Founder	17.8yrs	CA$100.00k	0.40% CA$ 144.3k
Markus Meile	Chief Financial Officer	9.8yrs	CA$60.00k	no data
Sam Ratnam	Director of Scientific & Regulatory Affairs	1.5yrs	no data	no data
Stewart McKelvey	Legal Counsel	no data	no data	no data
Kevin Jones	Head of Commercialization and Senior Director of Sales & Marketing	10.6yrs	no data	no data

10.2yrs

Average Tenure

Experienced Management: 47M's management team is seasoned and experienced (10.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hermes Chan	Co-Founder	24.1yrs	CA$100.00k	0.40% CA$ 144.3k
Steven Cummings	Independent Director	4.9yrs	no data	no data
Pascale Nini	Independent Director	1.8yrs	no data	no data
Thomas Bergmann	Independent Chairman	2.3yrs	no data	no data
Jianhe Mao	Independent Director	4.9yrs	no data	no data

4.9yrs

Average Tenure

Experienced Board: 47M's board of directors are considered experienced (4.9 years average tenure).

MedMira Management

Management criteria checks 4/4

Key information

Recent management updates

MedMira Inc., Annual General Meeting, Feb 09, 2024

MedMira Inc., Annual General Meeting, Feb 16, 2023

MedMira Inc. Announces Board Changes

Recent updates

Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)

New major risk - Revenue and earnings growth

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

MedMira Inc., Annual General Meeting, Feb 09, 2024

Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in FY 2022)

Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests

Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2022)

MedMira Inc., Annual General Meeting, Feb 16, 2023

First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)

MedMira Inc. Introduces VYRA TriDemic

Full year 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in FY 2021)

MedMira Inc. Announces Board Changes

Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2021)

MedMira Inc. Provides an Update on the New in Vitro Diagnostic Medical Devices Regulation in the European Market

MedMira Inc. Provides an Update on Regulatory Work for Canada for Its VYRA™ Product Line

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Medmira Inc. Announces VYRA CoV2Flu and Additional Regulatory Opportunities

MedMira Inc. announced that it has received CAD 1.665691 million in funding

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MedMira Inc. announced that it has received CAD 0.500108 million in funding

Third quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2020)

MedMira Inc. Announces Performance Update on World Health Organisation SARS-CoV2 Serology Standards

Second quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2020)

MedMira Inc. Announces Expansion of its Product Portfolio and Outlines the Company’s Covid-19 Market and Regulatory Plan

MedMira Inc. Announces Progress Update on its COVID-19 Product Family

New 90-day high: €0.25

Medmira Inc. Announces Product Update

MedMira Inc. Applies to US FDA to Obtain FDA Emergency Use Authorization for the REVEALCOVID-19TM Total Antibody Test

First quarter 2021 earnings released: EPS CA$0.001

Full year 2020 earnings released: CA$0.003 loss per share

MedMira Reports Additional Independent Performance Evaluation Results of REVEALCOVID-19™ Total Antibody Test

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure